Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery: A Case Report

Betty M. Luan-Erfe; Meltem Yilmaz; Bobbie Jean Sweitzer

doi:10.1213/XAA.0000000000001234

Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery: A Case Report

Betty M. Luan-Erfe, Meltem Yilmaz, Bobbie Jean Sweitzer

Anesthesiology

Research output: Contribution to journal › Article › peer-review

Abstract

Preoperative treatment of anemia with intravenous iron is inconsistent despite known risks of anemia and allogeneic blood transfusions. Limited research exists on the effectiveness of preoperative intravenous iron for chronic kidney disease (CKD) patients. We discuss a patient with severe anemia from advanced CKD, endometrial cancer, and menometrorrhagia. Her hemoglobin increased more than 2 g/dL after erythropoietin and two 750-mg ferric carboxymaltose infusions 5 weeks before a total abdominal hysterectomy and avoided blood transfusions perioperatively. By raising hemoglobin, preoperative intravenous iron and erythropoietin reduce blood transfusions and consequent risk of future allograft rejection and alloimmunization in potential transplant recipients.

Original language	English (US)
Pages (from-to)	e01234
Journal	A&A practice
Volume	14
Issue number	8
DOIs	https://doi.org/10.1213/XAA.0000000000001234
State	Published - Jun 1 2020

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1213/XAA.0000000000001234

Cite this

@article{7089fadf125645aba20e1adc3290323d,

title = "Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery: A Case Report",

abstract = "Preoperative treatment of anemia with intravenous iron is inconsistent despite known risks of anemia and allogeneic blood transfusions. Limited research exists on the effectiveness of preoperative intravenous iron for chronic kidney disease (CKD) patients. We discuss a patient with severe anemia from advanced CKD, endometrial cancer, and menometrorrhagia. Her hemoglobin increased more than 2 g/dL after erythropoietin and two 750-mg ferric carboxymaltose infusions 5 weeks before a total abdominal hysterectomy and avoided blood transfusions perioperatively. By raising hemoglobin, preoperative intravenous iron and erythropoietin reduce blood transfusions and consequent risk of future allograft rejection and alloimmunization in potential transplant recipients.",

author = "Luan-Erfe, {Betty M.} and Meltem Yilmaz and Sweitzer, {Bobbie Jean}",

year = "2020",

month = jun,

day = "1",

doi = "10.1213/XAA.0000000000001234",

language = "English (US)",

volume = "14",

pages = "e01234",

journal = "A&A practice",

issn = "2325-7237",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery

T2 - A Case Report

AU - Luan-Erfe, Betty M.

AU - Yilmaz, Meltem

AU - Sweitzer, Bobbie Jean

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Preoperative treatment of anemia with intravenous iron is inconsistent despite known risks of anemia and allogeneic blood transfusions. Limited research exists on the effectiveness of preoperative intravenous iron for chronic kidney disease (CKD) patients. We discuss a patient with severe anemia from advanced CKD, endometrial cancer, and menometrorrhagia. Her hemoglobin increased more than 2 g/dL after erythropoietin and two 750-mg ferric carboxymaltose infusions 5 weeks before a total abdominal hysterectomy and avoided blood transfusions perioperatively. By raising hemoglobin, preoperative intravenous iron and erythropoietin reduce blood transfusions and consequent risk of future allograft rejection and alloimmunization in potential transplant recipients.

AB - Preoperative treatment of anemia with intravenous iron is inconsistent despite known risks of anemia and allogeneic blood transfusions. Limited research exists on the effectiveness of preoperative intravenous iron for chronic kidney disease (CKD) patients. We discuss a patient with severe anemia from advanced CKD, endometrial cancer, and menometrorrhagia. Her hemoglobin increased more than 2 g/dL after erythropoietin and two 750-mg ferric carboxymaltose infusions 5 weeks before a total abdominal hysterectomy and avoided blood transfusions perioperatively. By raising hemoglobin, preoperative intravenous iron and erythropoietin reduce blood transfusions and consequent risk of future allograft rejection and alloimmunization in potential transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=85085978884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085978884&partnerID=8YFLogxK

U2 - 10.1213/XAA.0000000000001234

DO - 10.1213/XAA.0000000000001234

M3 - Article

C2 - 32496428

AN - SCOPUS:85085978884

SN - 2325-7237

VL - 14

SP - e01234

JO - A&A practice

JF - A&A practice

IS - 8

ER -

Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery: A Case Report

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this